EGFR and non-small cell lung carcinoma: For example, the PACIFIC trial demonstrated that durvalumab significantly improved PFS and OS when used after chemoradiation in stage III NSCLC, however, retrospective analyses suggest that this benefit was restricted to EGFR wild-type tumors [55].